大唐药业:2024年报净利润0.11亿 同比增长37.5%

Financial Performance - The company reported a basic earnings per share of 0.0400 yuan for 2024, an increase of 33.33% compared to 0.0300 yuan in 2023 [1] - Operating revenue reached 2.07 billion yuan, reflecting a growth of 10.11% from 1.88 billion yuan in the previous year [1] - Net profit for the year was 0.11 billion yuan, up 37.5% from 0.08 billion yuan in 2023 [1] - The return on equity improved to 2.20%, a 34.97% increase from 1.63% in the prior year [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 85.32 million shares, accounting for 50.44% of the circulating shares, with a decrease of 2.097 million shares compared to the previous period [1] - The largest shareholder, Hohhot Renhe Real Estate Development Co., Ltd., holds 77.16 million shares, representing 45.62% of the total share capital, with no change in holdings [2] - Several shareholders, including Hao Yantao and Sun Yali, have reduced their holdings, while new shareholders such as Yu Wenjuan and Zhao Shengxun have entered the top ten list [2] Dividend Distribution - The company announced a dividend distribution plan of 0.6 yuan per share (including tax) [2]